Please assess the completion status of the following clinical trial:

Trial Title: Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* One or more CNS hemangioblastomas not amendable to surgical resection or recurrent post resection~* Confirmed diagnosis of von-Hippel-Lindau disease~* No prior treatment with VEGF inhibitors~* Index hemangioblastomas lesion at least 5mm on MRI~* No major bleeding event from hemangioblastoma within 90 days~* KPS \> or equal to 60%~* Age \> or equal to 18 years~Exclusion Criteria:~* Prior treatment with VEGF inhibitors~* Major bleeding event from hemangioblastoma within 90 days~* Inability to comply with study and/or follow up procedures~* Life expectancy of less than 12 weeks~* Current or recent (within 4 weeks of the first infusion of this study) participation in an experimental drug study other than a Genentech sponsored bevacizumab cancer study~* Active malignancy will be permissible if treating physician deems that concurrent administration of bevacizumab is not contraindicated and that the patient would be able to complete with the other parameters of the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).